Citations

Clear

3138 citation(s) found for "Smith, AM".

Prospective Cohort Study Examining the Ability of Performance‐Based and Self‐Reported Frailty Measures to Predict 30‐Day Rehospitalizations After Kidney Transplantation
Lorenz, Elizabeth C. , Smith, Byron H. , Mour, Girish , Wadei, Hani M. , Kennedy, Cassie C. , Schinstock, Carrie A. , Kremers, Walter K. , Cheville, Andrea , LeBrasseur, Nathan K. , Rule, Andrew D. , Cheville, Andrea L , Rule, Andrew D , Smith, Byron , Schinstock, Carrie , Kennedy, Cassie C , LeBrasseur, Nathan K , Wadei, Hani M , Kremers, Walter K , Mour, Girish K

Mayo Clinic

Clinical Transplantation | August 19, 2024 | Volume: 38 | Issue: 8 | Pages: No page available

10.1111/ctr.15433 | PMID 39158949 Get It

ABSTRACTPerformance‐based measures of frailty are associated with healthcare utilization after kidney transplantation (KT) but require in‐person assessment. A promising alternative is self‐reported frailty. The goal of this study was to examine the ability of performance‐based and self‐reported frailty measures to predict 30‐day rehospitalizations after KT. We conducted a prospective, observational cohort study involving 272 adults undergoing KT at Mayo Clinic in Minnesota, Florida, or Arizona. We simultaneously measured frailty before KT using the physical frailty phenotype (PFP), the short physical performance battery (SPPB), and self‐report (the Patient‐Reported Outcomes Measurement Information System [PROMIS] 4‐item physical function short form v2.0). Both the PFP and self‐reported frailty were independently associated with more than a 2‐fold greater odds of 30‐day rehospitalizations, while the SPPB was not. To our knowledge, this is the first study to assess the prognostic value of all three of the above frailty measures in patients undergoing KT. The PFP is more prognostic than the SPPB when assessing the risk of 30‐day rehospitalizations; self‐reported frailty can complement the PFP but not replace it. However, the 4‐item survey assessing self‐reported frailty represents a simple way to identify patients undergoing KT surgery who would benefit from interventions to lower the risk of rehospitalizations.
Core outcomes in nerve surgery: development of a core outcome set for common peroneal (fibular) neuropathy
Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Desai, Ketan, Garozzo, Debora, Guedes, Fernando , Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | August 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2024.5.jns24614 | PMID 39151186 Get It

OBJECTIVE Common peroneal (fibular) neuropathy is the most common mononeuropathy of the lower extremity. Despite this, there are surprisingly few studies on the topic, and a knowledge gap remains in the literature. As one attempts to address this knowledge gap, a core outcome set (COS) is needed to guide the planning phases of future studies to allow synthesis and comparability of these studies. The objective of this study was to develop the COS–common peroneal neuropathy (CoPe) using a modified Delphi approach. METHODS A 5-stage approach was used to develop the COS-CoPe: 1) stage 1, consortium development; 2) stage 2, a literature review to identify potential outcome measures; 3) stage 3, a Delphi survey to develop consensus on outcomes for inclusion; 4) stage 4, a Delphi survey to develop definitions; and 5) stage 5, a consensus meeting to finalize COS and definitions. The study followed the COS–STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 23 participants, all neurological surgeons, representing 13 countries. The final COS-CoPe consisted of 31 data points/outcomes covering domains of demographics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 12 months. The consensus optimal time points for assessment were preoperatively and 3, 6, 12, and 24 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS and provided definitions, methods of implementation, and time points for assessment. The COS-CoPe should serve as a minimum set of data that should be collected in all future neurosurgical studies on common peroneal neuropathy. Incorporation of this COS should help improve consistency in reporting, data synthesis, and comparability, and should minimize outcome reporting bias.
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs, Jeremy W. , Stanek, C , Symeonidis, Argiris , Shih, Andrew W. , Gavriilaki, Eleni , Pavenski, Katerina , Moorehead, Amy , Mingot‐Castellano, María Eva , Daou, Laetitia , Arnold, Donald M. , Henrie, Ryan , Smith, Tyler , Sreenivasan, Gayatri , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Harrington, Thomas J., Byrnes, Diana M. , Bitsani, Aikaterini , Davis, Amanda K. , Robinson, Danielle H., Eichbaum, Quentin , Kaiafa, Georgia , Klapper, Ellen, Klein, Monica S., Kotsiou, Nikolaos , Lalayanni, Chrysavgi , Mandala, Evdokia , Alkhateb, Rahaf, Fortuny, Lisandro, Mellios, Zois, Papalexandri, Apostolia, Parsons, Meredith G , Wellard, Cameron , Jia, Shiyang , Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bouzid, Raïda , Coppo, Paul, Bloch, Evan M. , Adkins, Brian D. , Stanek, Caroline G , Booth, Garrett , Symeonidis, Argiris , Shih, Andrew W , Gavriilaki, Eleni , Moorehead, Amy , Peyvandi, Flora , Mancini, Ilaria , Raval, Jay S , Mingot-Castellano, Maria Eva , Crowe, Elizabeth P , Arnold, Donald M , Yamada, Chisa , Kotsiou, Nikolaos , Aldarweesh, Fatima , Schlueter, Annette J , Tormey, Christopher A , Wood, Erica M , Wheeler, Allison P , Yates, Sean G , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Parsons, Meredith G , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Pavenski, Katerina , Peyvandi, Flora , Agosti, Pasquale , Stephens, Laura D. , Raval, Jay S. , Pai, Menaka , Marques, Marisa B. , Yamada, Chisa , Robinson, Danielle H. , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Kapsali, Eleni , Perez-Alvarez, Ingrid , Aldarweesh, Fatima , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Coppo, Paul

Mayo Clinic

American Journal of Hematology | August 13, 2024 | Volume: 99 | Issue: 11 | Pages: 2063-2074

10.1002/ajh.27458 | PMID 39136282 Get It

AbstractPrior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5‐year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere—winter (December–February); spring (March–May); summer (June–August); autumn (September–November) and Southern Hemisphere—winter (June–August); spring (September–November); summer (December–February); autumn (March–May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%–31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
Steering the multidisciplinary landscape of vascular medicine: Collaboration as the key to success for aspiring vascular medicine specialists
Cohoon, Kevin P. , Porres‐Aguilar, Mateo , Tomihama, Roger T. , Thomas, Sneha , Rogers, Everett M., Brunton, Nichole , Henkin, Stanislav , Hornacek, Deborah , Secemsky, Eric A. , Buckley, Anthony , Brunton, Nichole E , Henkin, Stanislav , Secemsky, Eric A , Porres-Aguilar, Mateo , Tomihama, Roger

Mayo Clinic

Vascular Medicine | August 13, 2024 | Volume: 29 | Issue: 4 | Pages: 462-466

10.1177/1358863x241262723 | PMID 39135266 Get It

Nonpelvic comorbid symptoms of 45 patients with pain of pelvic venous origin, before and after treatment
Smith, Steven J. , Sichlau, Michael J. , Chen, Brenda, Knight, Dacre , Rowe, Peter C. , Smith, B Holly , Knight, Dacre R T , Rowe, Peter C

Mayo Clinic

Phlebology: The Journal of Venous Disease | August 10, 2024 | Volume: 40 | Issue: 2 | Pages: 66-79

10.1177/02683555241273109 | PMID 39126670 Get It

Objective To report the prevalence and severity of nonpelvic symptoms for patients with venous-origin chronic pelvic pain (VO-CPP) and to describe outcomes after pelvic vein stenting and embolization. Methods We retrospectively reviewed outcomes of 45 women with VO-CPP who underwent treatment with iliac vein stenting and/or embolization. Patients completed symptom-severity questionnaires before and after treatment that assessed for pelvic pain, and multiple other symptoms, including brain fog, anxiety, depression, musculoskeletal pain, fatigue, migraines and more. Results Patient age ranged from 18 to 65 years. The prevalence of common symptoms was as follows: migraines, 69%; brain fog, 76%; anxiety attacks, 58%; excess sweating, 64%; hip pain, 73%; diarrhea, 62%; constipation, 76%; and abdominal bloating, 82%. After treatment, most symptom scores improved by more than 50%; exceptions were excessive sweating (41% improvement) and bloating (47% improvement). Prevalence of individual symptoms that bundle into POTS ranged from 29% to 76%, where symptom improvement ranged from 23% to 59% after treatment. Overlapping individual symptoms characteristic of fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) were present in 64% to 82% of patients and all improved by 49% to 63% after treatment. Conclusions Pelvic venous flow abnormality is linked causally to a spectrum of interrelated symptoms, of which many can be bundled into named syndromes of unknown cause. With catheter- based treatment of pelvic venous pooling, nonpelvic symptom and syndrome scores improved.
Clinical Utility of Protein Language Models in Resolution of Variants of Uncertain Significance in KCNQ1, KCNH2 , and SCN5A Compared With Patch-Clamp Functional C
Ye, Dan , Garmany, Ramin , Martinez-Barrios, Estefania, Gao, Xiaozhi , Neves, Raquel , Tester, David J. , Bains, Sahej , Zhou, Wei , Giudicessi, John R. , Ackerman, Michael J. , Neves, Raquel Almeida Lopes , Bains, Sahej , Ye, Dan , Garmany, Ramin

Mayo Clinic

Circulation: Genomic and Precision Medicine | August 9, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circgen.124.004584 | PMID 39119706 Get It

BACKGROUND: Genetic testing for cardiac channelopathies is the standard of care. However, many rare genetic variants remain classified as variants of uncertain significance (VUS) due to lack of epidemiological and functional data. Whether deep protein language models may aid in VUS resolution remains unknown. Here, we set out to compare how 2 deep protein language models perform at VUS resolution in the 3 most common long-QT syndrome–causative genes compared with the gold-standard patch clamp. METHODS: A total of 72 rare nonsynonymous VUS (9 KCNQ1, 19 KCNH2 , and 50 SCN5A ) were engineered by site-directed mutagenesis and expressed in either HEK293 cells or TSA201 cells. Whole-cell patch-clamp technique was used to functionally characterize these variants. The protein language models, evolutionary scale modeling, version 1b and AlphaMissense, were used to predict the variant effect of missense variants and compared with patch clamp. RESULTS: Considering variants in all 3 genes, the evolutionary scale modeling, version 1b model had a receiver operating characteristic curve–area under the curve of 0.75 ( P =0.0003). It had a sensitivity of 88% and a specificity of 50%. AlphaMissense performed well compared with patch-clamp with an receiver operating characteristic curve-area under the curve of 0.85 ( P <0.0001), sensitivity of 80%, and specificity of 76%. CONCLUSIONS: Deep protein language models aid in VUS resolution with high sensitivity but lower specificity. Thus, these tools cannot fully replace functional characterization but can aid in reducing the number of variants that may require functional analysis.
KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
Bains, Sahej , Giammarino, Lucilla , Nimani, Saranda , Alerni, Nicolò , Tester, David J. , Kim, C.S. John, Christoforou, Nicolas , Louradour, Julien , Beslac, Olgica, Barbieri, Miriam , Matas, Lluis , Hof, Thomas , López, Rubén , Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Koren, Gideon , Zehender, Manfred, Brunner, Michael, Casoni, Daniela , Brooks, Gabriel , Ackerman, Michael J. , Odening, Katja E. , Brunner, Michael , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Horváth, András , Parodi, Chiara, Barry, Michael A. , Praz, Fabien

Mayo Clinic

European Heart Journal | August 8, 2024 | Volume: 45 | Issue: 36 | Pages: 3751-3763

10.1093/eurheartj/ehae476 | PMID 39115049 Get It

Abstract Background and Aims Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy. Methods KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes. Results KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P &lt; .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour. Conclusions This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Hoff, Fieke W. , Blum, William , Huang, Ying , Welkie, Rina Li , Swords, Ronan , Traer, Elie , Stein, Eytan M. , Lin, Tara L. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Chen, Timothy L. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja G., Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Borate, Uma , Byrd, John C. , Madanat, Yazan F. , Huang, Ying , Byrd, John C. , Duong, Vu H , Deininger, Michael , Zeidner, Joshua F , Smith, Catherine C , Koenig, Kristin L , Druker, Brian J , Mims, Alice S , Madanat, Yazan , Traer, Elie , Lin, Tara L , Byrd, John C , Archer, Kellie J. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Marcus, Sonja G., Levine, Ross L.

Mayo Clinic

Blood Advances | August 7, 2024 | Volume: 8 | Issue: 20 | Pages: 5297-5305

10.1182/bloodadvances.2024013685 | PMID 39110987 Get It

Abstract Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ≥60 years treated with lower-intensity treatment (LIT). We aimed to test the prognostic impact of ELN risk in patients with newly diagnosed (ND) AML aged ≥60 years given LIT and to further refine risk stratification for these patients. A total of 595 patients were included: 11% had favorable-, 11% intermediate-, and 78% had adverse-risk AML. ELN risk was prognostic for overall survival (OS) (P &lt; .001) but did not stratify favorable- from intermediate-risk (P = .71). Within adverse-risk AML, the impact of additional molecular abnormalities was further evaluated. Multivariable analysis was performed on a training set (n = 316) and identified IDH2 mutation as an independent favorable prognostic factor, and KRAS, MLL2, and TP53 mutations as unfavorable (P &lt; .05). A “mutation score” was calculated for each combination of these mutations, assigning adverse-risk patients to 2 risk groups: −1 to 0 points (“Beat-AML intermediate”) vs 1+ points (“Beat-AML adverse”). In the final refined risk classification, ELN favorable- and intermediate-risk were combined into a newly defined “Beat-AML favorable-risk” group, in addition to mutation scoring within the ELN adverse-risk group. This approach redefines risk for older patients with ND AML and proposes refined Beat-AML risk groups with improved discrimination for OS (2-year OS, 48% vs 33% vs 11%, respectively; P &lt; .001), providing patients and providers additional information for treatment decision-making.
Outcomes of surgical resection and vagus nerve stimulation in patients with medically refractory epilepsy and glutamic acid decarboxylase 65 antibody positivity
Zhao-Fleming, Hannah , Dubey, Divyanshu , Smith, Kelsey M. , Zhao-Fleming, Hannah H, Dubey, Divyanshu , Smith, Kelsey M , Guo, Yong , Britton, Jeffrey W.

Mayo Clinic

Epilepsia | August 7, 2024 | Volume: 65 | Issue: 10 | Pages: No page available

10.1111/epi.18086 | PMID 39110151 Get It

AbstractEpilepsy associated with high‐titer glutamic acid decarboxylase 65 (GAD65) IgG is often refractory to immunotherapies and antiseizure medication. This study sought to determine the efficacy of vagus nerve stimulation (VNS) and surgical resection in patients with drug‐resistant epilepsy associated with GAD65‐IgG. We retrospectively identified 15 patients with drug‐resistant epilepsy and high serum GAD65 antibody titers (>20 nmol·L−1) who underwent VNS implantation (n = 6), surgical resection (n = 7), or both (n = 2). A responder to VNS was defined as someone with a ≥50% reduction in seizure frequency, and a favorable surgical outcome was defined as Engel I–II. Of the eight patients who underwent VNS implantation, three (37.5%) were initially responders, but this was not sustained in two. Of the nine patients who underwent surgical resection, three (33.3%) had a favorable outcome; however, only one patient was seizure‐free at last follow‐up. Pathology was available in six patients, and only one had evidence of inflammation; this patient had seizure onset 1 year prior to surgery. Favorable seizure outcome correlated with older age at time of resective surgery, with a trend favoring later age of seizure onset. Taken together, surgical resection and VNS implantation may have limited efficacy in this patient population but can be considered in carefully selected cases.
Remimazolam As a Sole Sedative Agent for Gastrostomy Tubes Placed in the Interventional Radiology Suite: A Case Series
Shapiro, Anna Bovill , Smith, Michael A. , Moshe, Christine , Moshe, Christine T, Frey, Gregory T, Frey, G. , Chadha, Ryan

Mayo Clinic

A&A Practice | August 6, 2024 | Volume: 18 | Issue: 8 | Pages: e01839

10.1213/xaa.0000000000001839 | PMID 39105528 Get It

Remimazolam is an ultrashort acting intravenous sedative-hypnotic approved for procedural sedation. We report a series of 8 cases of radiographically placed gastrostomy tubes using remimazolam as the sole anesthetic agent. Interventional radiology (IR) gastrostomy tube placement entails anesthetizing often complex patients in a nonoperating room environment. All 8 patients reported here underwent successful gastrostomy tube placement without the need for conversion to general anesthesia. Remimazolam is a feasible option to sedate patients for gastrostomy tube placement in the IR suite.